Trastuzumab emtansine (Kadcyla®) is indicated as a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 20/01/2020 |
| Rapid review completed | 27/02/2020 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of trastuzumab emtansine compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 04/03/2020 |
| Pre-submission consultation with Applicant | 31/03/2020 |
| Current status | Awaiting HTA submission from company |